Table 4 Mean averted and incremental cost per patient due to each CUP

MO29499

Alectinib

Non-Small Cell Lung Cancer 1

€ 20,350

€ 44,860

-

-

SoC1 [42];

SoC2 [42, 43]

-

€ 106

-

-

ML40066

Alectinib

Non-Small Cell Lung0 Cancer 2

€ 2,984

€ 9,700

€ 11,080

€ 14,500

SoC1 [44, 45]

SoC2 and SoC3 [46]

SoC4 [44]

-

-

-

-

ML39740

Atezolizumab

Urothelial Carcinoma

€ 3,674

€ 12,902

€ 32,223

-

SoC1 [47, 48]

SoC2 [49, 50]

SoC3 [50, 73]

-

-

€ 60

€ 1,922

AL41528

Atezolizumab

Non-Small Cell Lung Cancer

€ 9,395

€ 10,732

€ 33,229

-

SoC1 and SoC2 [46]

SoC3 [51, 52, 72]

-

-

€ 11

€ 1,404

AL41712

Atezolizumab

Triple-Negative Breast Cancer

€ 7,104

-

-

-

SoC1 [53, 54]

-

-

€ 90

€ 1,848

M029476

Cobimetinib

Melanoma

€ 33,824

€ 39,991

€ 41,274

-

SoC1 [55]

SoC2 [55, 56]

SoC3 [55]

€ 16,086

-

€ 125

€ 2,029

MA30130

Ocrelizumab

Primary Progressive Multiple Sclerosis

€ 3,002

-

-

-

SoC1 [57, 58]

-

€ 20

€ 27

€ 2,139

AG40852

Entrectinib

Non-Small Cell Lung Cancer

€ 79,019

-

-

-

SoC1 [42]

-

-

-

-

AG40661

Polatuzumab Vedotin

Diffuse Large B-Cell Lymphoma

€ 55,583

€ 56,658

-

-

SoC1 [59, 60, 69, 70, 71]

SoC2 [60, 61, 62]

-

-

€ 151

€ 2,488

AG41381

Risdiplam

Spinal Muscular Atrophy Type 1

€ 200,000

-

-

-

SoC1 [63]

-

-

-

-

AL41711

Trastuzumab emtansine

Breast Cancer

€ 3,780

€ 19,576

-

-

SoC1 and SoC2 [64]

-

€ 253

-

-

Mean costfor hospitalised patients

€ 2,184